Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Ocean University of China · The University of Texas Health Science Center at Houston · +5 more institutions
Abstract
Non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) has become the leading cause of liver disease worldwide. NASH, an advanced form of NAFL, can be progressive and more susceptible to developing cirrhosis and hepatocellular carcinoma. Currently, lifestyle interventions are the most essential and effective strategies for preventing and controlling NAFL without the development of fibrosis. While there are still limited appropriate drugs specifically to treat NAFL/NASH, growing progress is being seen in elucidating the pathogenesis and identifying therapeutic targets. In this review, we discussed recent developments in etiology and prospective therapeutic targets, as well as pharmacological candidates…
Citation impact
- FWCI
- 45.60
- Percentile
- 100%
- References
- 639
Authors
10- XXXiaohan XuCorresponding
Ocean University of China
- KLKyle L. Poulsen
The University of Texas Health Science Center at Houston
- LWLijuan Wu
Qingdao National Laboratory for Marine Science and Technology, Ocean University of China
- SLShan Liu
Qingdao National Laboratory for Marine Science and Technology
- TMTatsunori Miyata
Kumamoto University
Topics & keywords
- Steatohepatitis
- Fatty liver
- Cirrhosis
- Medicine
- Bioinformatics
- Hepatocellular carcinoma
- Cancer research
- Biology
- Good health and well-being